Mara Epstein to Aged, 80 and over
This is a "connection" page, showing publications Mara Epstein has written about Aged, 80 and over.
Connection Strength
0.705
-
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 06 15; 152(12):2485-2492.
Score: 0.106
-
Epstein MM, Sundaresan D, Fair M, Fouayzi H, Warner ET, Garber LD, Gurwitz JH, Field TS. Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central Massachusetts. Cancer Causes Control. 2022 Oct; 33(10):1313-1323.
Score: 0.102
-
Epstein MM, Saphirak C, Zhou Y, LeBlanc C, Rosmarin AG, Ash A, Singh S, Fisher K, Birmann BM, Gurwitz JH. Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf. 2020 01; 29(1):69-76.
Score: 0.084
-
Casta?eda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintr?n CR, Birmann BM, Epstein MM. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer. 2020 01 01; 146(1):35-43.
Score: 0.081
-
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
Score: 0.071
-
Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012 Sep 05; 104(17):1335-42.
Score: 0.051
-
Frendl DM, FitzGerald G, Epstein MM, Allison JJ, Sokoloff MH, Ware JE. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool. PLoS One. 2020; 15(12):e0240039.
Score: 0.023
-
Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
Score: 0.022
-
Frendl DM, Epstein MM, Fouayzi H, Krajenta R, Rybicki BA, Sokoloff MH. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data. Cancer Causes Control. 2020 Sep; 31(9):861-867.
Score: 0.022
-
Meyer MS, Mucci LA, Andersson SO, Andr?n O, Johansson JE, Tretli S, Adami HO. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol. 2010 Sep; 58(3):427-32.
Score: 0.022
-
Lee C, Check DK, Manace Brenman L, Kushi LH, Epstein MM, Neslund-Dudas C, Pawloski PA, Achacoso N, Laurent C, Fehrenbacher L, Habel LA. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.021
-
Banegas MP, Rivera DR, O'Keeffe-Rosetti MC, Carroll NM, Pawloski PA, Tabano DC, Epstein MM, Yeung K, Hornbrook MC, Lu C, Ritzwoller DP. Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML. J Natl Compr Canc Netw. 2019 10 01; 17(10):1166-1172.
Score: 0.021
-
Mack DS, Epstein MM, Dub? C, Clark RE, Lapane KL. Screening mammography among nursing home residents in the United States: Current guidelines and practice. J Geriatr Oncol. 2018 11; 9(6):626-634.
Score: 0.019
-
Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J, Johnson CC. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 01; 29(1):143-156.
Score: 0.018
-
Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA. Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. Carcinogenesis. 2016 Mar; 37(3):262-8.
Score: 0.016
-
Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42.
Score: 0.014
-
Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
Score: 0.012